Clinical Trial Search

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate — 14 Participants

Primary: PSA Response Rate — 0 percentage of participants

Primary: PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy — 0.0 proportion with 6+ months PFS

Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale

Primary: Overall Response Rate — 6 percentage of patients

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns

Primary: Biochemical Response Rate — 0 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants

Primary: PSA Progression-free Survival — 20.8; 16.5 Months — p=0.83

Primary: Number of Participants Progression-free at 18 Months — 0 participants

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Overall Response Rate (ORR) — 50 percentage of participants

Primary: Number of Participants With Change in PSA Response — 2; 0 Participants

Primary: PSA Reduction ≥ 50% — 0 participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44

Primary: Best Overall Response — 0; 14; 21; 8 Participants

Primary: Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…

Primary: Proportion of Participants With Undetectable Serum Prostate-specific Antigen (PSA) — 0; 0.308 proportion of participants

Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2

Primary: Prostate Specific Antigen (PSA) Response Rate — 6 Participants

Primary: Progression Free Survival — 16.1 months

Primary: 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) — 2; 8 participants

Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46

Primary: Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer — 19 Participants

Primary: Maximum Tolerated Dose (MTD) of Temsirolimus (Phase I) — 25 mg

Primary: Number of Patients With Undetectable PSA — 5 Participants